Evolus, Inc. (EOLS) News
Filter EOLS News Items
EOLS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EOLS News Highlights
- EOLS's 30 day story count now stands at 2.
- Over the past 12 days, the trend for EOLS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest EOLS News From Around the Web
Below are the latest news stories about EVOLUS INC that investors may wish to consider to help them evaluate EOLS as an investment opportunity.
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in EuropeNEWPORT BEACH, Calif., December 20, 2023--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced it has entered into a definitive agreement with Symatese to be the exclusive distributor in the United Kingdom (U.K.) and Europe of four unique dermal fillers in late-stage development with anticipated regulatory clearances in second half of 2024 and commercialization under the brand name Estyme® (pronounced "esteem") fillers in 2025 |
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEWPORT BEACH, Calif., December 08, 2023--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in December of an aggregate of 28,328 restricted stock units (RSUs) of the company’s common stock to 7 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a gran |
Evolus, Inc. (NASDAQ:EOLS) Q3 2023 Earnings Call TranscriptEvolus, Inc. (NASDAQ:EOLS) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good afternoon, and welcome to the Evolus Third Quarter 2023 Earnings Conference Call. [Operator Instructions]. I would now like to turn the conference over to your host, Mr. Ned Mitchell from Investor Relations. Ned? Ned Mitchell: Thank you, operator, and welcome to everyone […] |
Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®NEWPORT BEACH, Calif., November 07, 2023--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the third quarter ended September 30, 2023. |
"Extra-Strength" 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual MeetingNEWPORT BEACH, Calif., November 06, 2023--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced results from the Phase 2 clinical study evaluating the "extra-strength" 40U dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), the only neurotoxin dedicated exclusively to aesthetics. Final data were presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting on November 3, 2023, |
Evolus to Participate in November Investor ConferencesNEWPORT BEACH, Calif., November 01, 2023--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will present at the following investment conferences in November. |
Evolus to Report Third Quarter 2023 ResultsNEWPORT BEACH, Calif., October 25, 2023--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, after the U.S. financial markets close. |
Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual MeetingNEWPORT BEACH, Calif., October 25, 2023--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sue Ellen Cox M.D. will present final results from the Phase 2 study evaluating the safety, efficacy and duration of effect of 40U PrabotulinumtoxinA-xvfs at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting on November 3, 2023, in Chicago during an independent medical education session. |
Investors in Evolus (NASDAQ:EOLS) have seen splendid returns of 135% over the past three yearsEvolus, Inc. ( NASDAQ:EOLS ) shareholders might be concerned after seeing the share price drop 15% in the last month... |
7 Must-Own Small-Cap Stocks That Could Outperform the MarketIf you’re ready to absorb significant risk for the chance of ridiculous upside, these small-cap stocks to buy may be just for you. |